# Nextech Invest Ltd.

> Institutional holdings reported to the SEC as of Q4 2024 on Form 13F. CIK 1911010. Source: https://holderbook.com/funds/1911010-nextech-invest-ltd/

- Reported value: $616.4M
- Positions: 15
- Weight of the ten largest: 93.6%
- Filed: 2025-02-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $332.5M | 7,601,087 | 53.9% | 13 |
| TYRA BIOSCIENCES INC | [TYRA](https://holderbook.com/stocks/TYRA/) | $56.4M | 4,055,861 | 9.1% | 13 |
| ORIC PHARMACEUTICALS INC | [ORIC](https://holderbook.com/stocks/ORIC/) | $42.7M | 5,285,714 | 6.9% | 7 |
| CARGO THERAPEUTICS INC | [CRGX](https://holderbook.com/stocks/CRGX/) | $38.1M | 2,642,502 | 6.2% | 5 |
| ARVINAS INC | [ARVN](https://holderbook.com/stocks/ARVN/) | $27.0M | 1,408,394 | 4.4% | 13 |
| MERSANA THERAPEUTICS INC COM | [MRSN](https://holderbook.com/stocks/MRSN/) | $17.3M | 12,067,246 | 2.8% | 5 |
| TANGO THERAPEUTICS INC | [TNGX](https://holderbook.com/stocks/TNGX/) | $17.1M | 5,533,980 | 2.8% | 6 |
| ZYMEWORKS INC | [ZYME](https://holderbook.com/stocks/ZYME/) | $16.3M | 1,113,946 | 2.6% | 2 |
| RELAY THERAPEUTICS INC | [RLAY](https://holderbook.com/stocks/RLAY/) | $15.8M | 3,846,409 | 2.6% | 12 |
| CULLINAN THERAPEUTICS INC | [CGEM](https://holderbook.com/stocks/CGEM/) | $13.9M | 1,141,145 | 2.3% | 13 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $11.6M | 1,476,998 | 1.9% | 2 |
| ARS PHARMACEUTICALS INC | [SPRY](https://holderbook.com/stocks/SPRY/) | $9.9M | 936,729 | 1.6% | 13 |
| CONTEXT THERAPEUTICS INC | [CNTX](https://holderbook.com/stocks/CNTX/) | $7.8M | 7,419,355 | 1.3% | 3 |
| SILENCE THERAPEUTICS PLC | [SLN](https://holderbook.com/stocks/SLN/) | $6.6M | 952,400 | 1.1% | 4 |
| BOUNDLESS BIO INC | [BOLD](https://holderbook.com/stocks/BOLD/) | $3.6M | 1,228,069 | 0.6% | 4 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q4 2024 | -21.2% | +2.1% | -23.4% | 100% |
| Q3 2024 | +16.2% | +5.4% | +10.7% | 100% |
| Q2 2024 | -9.9% | +4.0% | -14.0% | 100% |
| Q1 2024 | +12.6% | +10.0% | +2.6% | 92% |
| Q4 2023 | +9.3% | +11.2% | -1.8% | 91% |
| Q3 2023 | -9.6% | -3.6% | -6.0% | 100% |
| Q2 2023 | +7.4% | +8.3% | -0.9% | 100% |
| Q1 2023 | -2.4% | +7.0% | -9.4% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q4 2024 | $616.4M | 15 |
| Q3 2024 | $712.3M | 15 |
| Q2 2024 | $594.5M | 13 |
| Q1 2024 | $630.8M | 12 |
| Q4 2023 | $536.8M | 11 |
| Q3 2023 | $330.0M | 14 |
| Q2 2023 | $294.2M | 13 |
| Q1 2023 | $239.6M | 12 |
| Q4 2022 | $251.4M | 14 |
| Q3 2022 | $309.6M | 14 |
| Q2 2022 | $296.5M | 14 |
| Q1 2022 | $350.3M | 14 |